Apigenin, CD38 Inhibition, and NAD: The Flavonoid Mechanism and Emerging Human Evidence

Apigenin, a flavone abundant in parsley, chamomile, and celery, has moved from "calming tea polyphenol" to a candidate adjunct in NAD-restoration research over the past decade. The mechanism — inhibition of CD38, the dominant NAD-degrading ectoenzyme that increases with age — is biologically tidy. Whether it survives translation into clinical endpoints is still being tested.

The CD38 story

CD38 expression in tissues rises substantially with age and accounts for a large fraction of age-related NAD decline in mouse and human tissue [1]. In CD38-knockout mice, NAD levels are preserved into old age and the metabolic phenotype of aging is attenuated. Pharmacological CD38 inhibition was proposed as a way to recapitulate the genetic effect, and apigenin was identified in a screen of natural-product CD38 inhibitors at low micromolar potency [2].

Preclinical translation

In aged mice, apigenin treatment raises tissue NAD levels, improves glucose tolerance, and reduces inflammatory markers [3]. Effects are most pronounced when CD38 inhibition is combined with an NAD precursor (NR or NMN), suggesting that apigenin's primary value may be in slowing NAD breakdown rather than driving synthesis. Combination trials with NR plus apigenin have been proposed but human data remain limited [4].

The human bioavailability constraint

Apigenin's oral bioavailability is poor — typically below 5 percent — and plasma concentrations after dietary or supplemental doses rarely reach the micromolar range required for measurable CD38 inhibition in vitro [5]. Tissue accumulation may be more relevant than plasma levels, but human tissue-level pharmacokinetic data are sparse.

The chamomile and senolytic angles

Chamomile tea (the historical source of apigenin) and apigenin supplements have been studied for sleep and anxiety in small placebo-controlled trials, with modest positive findings unrelated to NAD biology [6]. Separately, apigenin has been investigated as part of senolytic combinations (often with quercetin and fisetin) in pilot trials in diabetic kidney disease and idiopathic pulmonary fibrosis [7]. These senolytic trials are early and have not specifically isolated apigenin's contribution.

Where this leaves consumers

Apigenin at 50-100 mg/day is unlikely to produce dramatic NAD or longevity effects on its own, but the mechanistic story is plausible enough that careful study is ongoing. Anyone interested in NAD biology has better-established options in NR and NMN with their own (also incomplete) clinical record. Apigenin's strongest near-term evidence remains for sleep-quality improvements through chamomile extracts, not for CD38-mediated NAD preservation.

Drug interactions through CYP modulation

Apigenin inhibits several cytochrome P450 enzymes — particularly CYP1A2 and CYP2C9 — at concentrations within the range achievable by high-dose supplementation. This raises the possibility of interactions with warfarin, theophylline, fluvoxamine, and certain NSAIDs [8]. The clinical magnitude is uncertain but plausibly meaningful enough that anyone on narrow-therapeutic-index drugs should not start high-dose apigenin without prescriber awareness.

How to think about it

For now, apigenin is a compound with a clean mechanistic hypothesis, encouraging preclinical data, and limited human translation. Daily dietary intake from parsley, chamomile tea, and celery may already provide low-grade exposure. Whether the supplement-dose escalation produces enough tissue concentration to inhibit CD38 in vivo is unresolved. The combination-with-NAD-precursor strategy is the most interesting near-term clinical question.

For consumers asking about apigenin specifically for sleep, the more cleanly supported intervention is chamomile tea or standardized chamomile extract for mild anxiety and sleep-onset difficulty, with apigenin as a marker compound rather than the sole driver of effect. The CD38 and NAD-preservation angle is mechanistically appealing but should be considered investigational until human dose-response and tissue-level pharmacokinetic data clarify the translational picture.